"This grant will enable Amarantus to explore the full breadth of the MANF opportunity," said Gerald E. Commissiong, President & CEO of Amarantus. "As our development program for Parkinson's progresses towards the critical milestone of identifying the best delivery target(s) for MANF, identifying additional disease targets for MANF therapy could significantly increase the value of our intellectual property portfolio and make Amarantus more attractive to potential partners."